SCHEMBL19631472

SCHEMBL19631472

COC(=O)/C=C/c1ccc(C(=O)Nc2cnc3ccccc3c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
KMT2A Q03164 1/20 0.67
NPC1 O15118 4/20 0.65
RAB9A P51151 4/20 0.65
MITF O75030 1/20 0.65
XBP1 P17861 1/20 0.65
PAX8 Q06710 1/20 0.65
KLF5 Q13887 1/20 0.65
KDR P35968 3/20 0.64
TRPV1 Q8NER1 12/20 0.63
ALDH1A1 P00352 2/20 0.60
HPGD P15428 1/20 0.54
TSHR P16473 1/20 0.54
HSD17B10 Q99714 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19631304 0.86 KDR (0.67) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL21356567 0.86 KDR (0.67) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL19631346 0.86 NPC1 (0.69) KDM4ESMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL5284425 0.83 TRPV1 (0.71) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL5284418 0.83 TRPV1 (0.71) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL19616647 0.82 NPC1 (0.76) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL19631296 0.81 KDM4E (0.69) KDM4ESMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL5909673 0.81 KDR (0.65) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL5909669 0.81 KDR (0.65) KDM4ESMN1; SMN2NPC1RAB9AMITF
SCHEMBL29647749 0.81 KDR (0.81) KDM4ESMN1; SMN2NPC1RAB9AMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN UNIV TAIPEI MEDICAL (TW) 2025-11-13 US disclosed
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-30 US disclosed
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-11 US disclosed
EP-3458444-B1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF UNIV TAIPEI MEDICAL (TW) 2022-06-22 EP disclosed
EP-3458444-B1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF UNIV TAIPEI MEDICAL (TW) 2022-06-22 EP disclosed
WO-2021013163-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (CN) 2021-01-28 WO disclosed
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2019-09-19 US disclosed
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2019-09-19 US disclosed
WO-2017200966-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF HDAC1, HDAC11, HDAC7 KDM4E 216/4885SMN1; SMN2 3282/4885KMT2A 77/4885
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC5 KDM4E 480/4885SMN1; SMN2 574/4885KMT2A 78/4885
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC2 KDM4E 424/4885SMN1; SMN2 722/4885KMT2A 60/4885
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof HDAC1, HDAC11, HDAC7 KDM4E 216/4885SMN1; SMN2 3282/4885KMT2A 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.